2023 International Congress » Parkinson’s Disease: Clinical Trials

Meeting: 2023 International Congress

15-year effects of initiating treatment for Parkinson’s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation

C. Clarke, C. Rick, S. Patel, R. Wooley, N. Rowland, J. Futterer, R. Ottridge, C. Jenkinson, R. Gray (Birmingham, United Kingdom)

A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.

S. Pasternak, C. Silveira, K. Coleman, R. Garcia, J. Wells, M. Borrie, P. Macdonald, R. Bartha, M. Jenkins, S. Morrow, D. Mendonca, G. Zou, E. Finger, T. Rupar, R. Tirona, M. Jog (London, Canada)

A pilot, randomized, placebo controlled, double-blinded, delayed start trial of Modafinil for the treatment of Freezing of Gait in Parkinson’s disease.

T. Virmani, L. Pillai, R. Landes, A. Glover, M. Lotia, R. Dhall, E. Garcia-Rill (LITTLE ROCK, USA)

A staged screening paradigm to identify people at risk of Parkinson’s disease in the Parkinson’s Progression Markers Initiative

E. Brown, A. Siderowf, T. Simuni, T. Sherer, M. Brumm, C. Caspell-Garcia, R. Kurth, C. Gochanour, M. Kuhl, M. Korell, J. Valverde Twiggs, C. Stanley, L. Concha, C. Soto, K. Marek, C. Tanner (San Francisco, USA)

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (BASEL, Switzerland)

Access-PD – a ‘next generation’ registry to accelerate Parkinson’s disease research

Y. Chang, A. Noyce (London, United Kingdom)

Agreement between Parkinson disease Home Diary and observer assessments before and after structured patient training

C. Janz, J. Timpka, M. Löhle, A. Bremer, F. Gandor, G. Ebersbach, A. Storch, P. Odin (Lund, Sweden)

Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson’s disease.The AMBITIOUS Study Protocol

F. Colucci, M. Avenali, R. de Micco, A. Bacila, S. Cerri, G. Cuconato, V. Franco, D. Franciotta, C. Ghezzi, M. Gastaldi, C. Galandra, G. Germani, P. Mitrotti, G. Ongari, I. Palmieri, M. Picascia, A. Pichiecchio, F. Esposito, M. Cirillo, F. Di Nardo, S. Aloisio, M. Siciliano, M. Fusar Poli, M. Stanziano, B. Garavaglia, F. Cazzaniga, C. Reale, I. Tramacere, S. Priori, P. Amami, S. Piacentini, MG. Bruzzone, M. Grisoli, F. Moda, R. Eleopra, A. Tessitore, EM. Valente, R. Cilia (Milan, Italy)

Anle138b-P1-02: A randomised, double-blinded, placebo-controlled phase 1b study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of the oligomer modulator anle138b in Parkinson´s disease

J. Levin, N. Singh, S. Melbourne, A. Morgan, C. Carroll, U. Fietzek, S. Ryazanov, A. Leonov, CH. Griesinger, F. Schmidt, D. Weckbecker, K. Prager, T. Matthias, A. Giese (Wendelsheim, Germany)

Apomorphine sublingual film for OFF episodes in PD: Impact on orthostatic hypotension during dose-optimization

W. Jost, M. Coelho, M. Fonseca, G. Castilla-Fernández, D. Magalhães, CK. Denecke Muhr (Wolfach, Germany)

Arm swing deviations in patients with PD at different gait velocities

S. Mainka, G. Ebersbach (Beelitz-Heilstaetten, Germany)

Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson’s Disease

T. Kustermann, G. Pagano, H. Svoboda, T. Nikolcheva, K. Taylor (Basel, Switzerland)

Benefits of Physician-Pharmacist Collaboration on Patient Outcomes in Parkinson’s Disease and Movement Disorders Clinic

P. Techa-Angkoon, Y. Pitakpatapee, W. Saengphatrachai, P. Srivanitchapoom, T. Suansanae (Bangkok, Thailand)

Challenges with oral anti-parkinsonian medications and opportunities with continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDP/CDP) for treatment of advanced Parkinson’s Disease (aPD)

J. Aldred, M. Soileau, C. Yan, T. Brion, A. Bellenger, J. Suh, C. O'Donnell, P. Kukreja, M. Facheris, A. Shewale, R. Kumar (Spokane, USA)

Characterisation of OFF-Time in Levodopa-Treated Parkinson’s Patients: A Post-hoc Analysis of an Exploratory Trial

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, B. Guimarães, J-F. Rocha (Lisbon, Portugal)

Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study – results of the Belgian subgroup

V. van Iseghem, N. de Klippel, PH. Bourgeois, P. Bourgeois, T. Warlop, S. Dethy, E. Parmentier, D. Uyttersprot, K. Onuk, G. Garraux (Kortrijk, Belgium)

Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson’s disease: interim analysis of a pilot add-on, randomized, controlled, pragmatic clinical trial

S. Yuen, KK. Chua, L. Zhong, KW. Chan, C. Chan, CP. Ho, KL. Chan, E. Han, K. Pang, ZX. Lin, V. Mok, N. Cheung, AY. Lau, M. Li (Hong Kong, Hong Kong)

Chinese medicine pattern diagnostic criteria in clinical and epidemiological studies of Parkinson’s disease: a systematic review

CP. Ho, S. Yuen, C. Chan, M. Li, KK. Chua (Hong Kong, Hong Kong)

Chinese proprietary medicine as adjunct treatment for Parkinson’s disease: a systematic review and meta-analysis

S. Yuen, KK. Chua, SC. Chen, CP. Ho, C. Chan, M. Li (Hong Kong, Hong Kong)

Clinic versus home dose optimization of apomorphine sublingual film in Parkinson’s Disease: cross-study comparison of safety

SH. Isaacson, J. Kassubek, R. Pahwa, E. Pappert, S. Wu, C. Denecke Muhr (Boca Raton, USA)

Connectomic DBS informed multifocal transcranial direct current stimulation (tDCS) in Parkinson’s Disease: a crossover double blinded study

L L. Goede, S. Oxenford, D. Kroneberg, G M. Meyer, N. Rajamani, C. Neudorfer, P. Krause, R. Lofredi, M D. Fox, A A. Kühn, A. Horn (Berlin, Germany)

Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study

J. Aldred, A. Amelin, A. Antonini, B. Bergmans, F. Bergquist, M. Bouchard, K. Budur, C. Carroll, K. Chaudhuri, S. Criswell, E. Danielsen, E. Freire Alvarez, F. Gandor, J. Jia, T. Kimber, H. Mochizuki, W. Robieson, A. Spiegel, D. Standaert, S. Talapala, M. Facheris, V. Fung (Spokane, USA)

Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study

W. Poewe, A. Ellenbogen, F. Stocchi, L. Adar, L. Salin, R. Case, T. Yardeni, N. Giladi (Innsbruck, Austria)

Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study

O. Rascol, A. Albanese, A. Ellenbogen, J. Ferreira, N. Giladi, T. Gurevich, S. Hassin-Baer, J. Hernandez-Vara, S. Isaacson, K. Kieburtz, P. Lewitt, L. Lopez-Manzanares, CW. Olanow, R. Pahwa, W. Poewe, H. Sarva, F. Stocchi, T. Yardeni, L. Adar, L. Salin, N. Lopes, N. Sasson, R. Case, A. Espay (Toulouse, France)

Correlation between oculometric measures, disease severity, and clinical assessment in patients with Parkinson’s disease

J. Reiner, L. Franken, E. Raveh, I. Rosset, R. Kreitman, E. Ben-Ami, R. Djaldetti (Petah Tikva, Israel)

Cost-effectiveness of Lee Silverman Voice Treatment LOUD (LSVT®) versus NHS Speech and Language Therapy versus control for dysarthria in Parkinson’s disease: An economic evaluation alongside the PD COMM trial

C. Clarke, Z. Abdali, S. Jowett, C. Rick, M. Brady, R. Woolley, C. Burton, S. Patel, P. Masterson-Algar, A. Nicoll, C. Smith, N. Ives, G. Beaton, S. Dickson, R. Ottridge, H. Nankervis, C. Sackley (Birmingham, United Kingdom)

Dance for Parkinson’s disease to improve gait and balance: clinical assessments vs. objective measures.

HHN. Kalyani, K. Sullivan, G. Moyle, S. Brauer, E. Jeffrey, G. Kerr (Colombo, Sri Lanka)

Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial

O. Rascol, F. Ory-Magne, JP. Azulay, L. Defebvre, JL. Houeto, D. Maltete, P. Remy, A. Foubert-Samier, A. Sommet, C. Thalamas, S. Thobois, JC. Corvol, N. Ns-Park/fcrin (Toulouse, France)

Deep Brain Stimulation in Parkinson’s Disease Patients: A One Year Follow-up in the Understudied Geography of Brazil

M. Faria, A. Novicki, F. Godinho, Y. Souza, J. Woods, K. Stromberg, R. Paolillo, C. Rocha (Belo Horizonte, Brazil)

Design of a time-to-event study in GBA Parkinson’s Disease patients: Efficacy and safety of BIA 28-6156, an allosteric activator of beta-glucocerobridase (GCase)

L. Magalhães, M. Fonseca, G. Castilla-Fernández, R. Costa, D. Simon, J. Holenz, N. Mendonça (Coronado, Portugal)

Developement and acceptability testing of a patient decision aid on levodopa/carbidopa intestinal gel.

C-C. Cayer, IBB. Beaulieu-Boire, A-T. Tanguay (Sherbrooke, Canada)

Development and Validation of an Algorithm to Automatically Assess Motor Symptoms of Parkinson’s Disease

S. Sekimoto, G. Oyama, Y. Nonomiya, T. Hayashi, M. Soshi, S. Chiba, N. Hattori (Bunkyo-ku, Japan)

Digital gait and turning impairments (quality but not quantity) during daily life are more severe in retrospective fallers compared to non-fallers with Parkinson’s disease

V. Shah, C. Silva-Batista, P. Burgos, A. Ragothaman, P. Carlson-Kuhta, K. Sowalsky, F. Horak, M. Mancini (Porltand, USA)

Does baseline expectation of benefit predict outcome in SURE-PD3, a Randomized, Double-Blind, Placebo-Controlled, Phase III trial of Inosine in Parkinson’s disease?

T. Mestre, E. Macklin, A. Lang, M. Schwarzschild (Ottawa, Canada)

Dopamine transporter in the brain is linked to irritable bowel syndrome in Parkinson´s disease

K. Murtomäki, J. Joutsa, T. Mertsalmi, E. Jaakkola, E. Mäkinen, R. Levo, M. Eklund, S. Nuuttila, E. Pekkonen, T. Noponen, T. Ihalainen, V. Kaasinen, F. Scheperjans (Helsinki, Finland)

Dopaminergic neuronal cell therapy for Parkinson’s Disease: results from a phase 1 study of Bemdaneprocel

C. Henchcliffe, H. Sarva, A. Lozano, A. Fasano, S. Kalia, C. Brennan, K. Yu, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (Orange, USA)

Early onset of efficacy during titration in US phase 3 open-label InfusON trial of apomorphine subcutaneous infusion for Parkinson’s disease motor fluctuations

S. Isaacson, G. Ceresoli-Borroni, A. Espay, R. Pahwa, P. Agarwal, H. Shill, J. Hui, K. Dashtipour, M. Lew, P. Qin, P. Lewitt (Boca Raton, USA)

Effect of dietary caffeine on brain dopamine transporter binding in Parkinson’s disease

E. Saarinen, T. Kuusimäki, K. Lindholm, EA. Honkanen, T. Noponen, M. Seppänen, K. Murtomäki, T. Mertsalmi, E. Jaakkola, E. Mäkinen, M. Eklund, S. Nuuttila, R. Levo, KR. Chaudhuri, A. Antonini, J. Joutsa, F. Scheperjans, V. Kaasinen (Turku, Finland)

Effect of Recognition of Vertical Posture on Forward Bending Posture in Patients with Parkinson’s Disease: A Multicenter Observational Study

M. Shiraishi, K. Mikami, H. Kamo, T. Kamo, T. Tsunemi, Y. Okuma, K. Fujimoto, Y. Yokota, S. Nogawa, T. Osada, M. Seki, H. Nagayama, T. Hatano, H. Nakajima, K. Suzuki, T. Yamamoto, Y. Yamano, N. Hattori, M. Ijima (Kawasaki, Japan)

Effects of Boxing and conventional physiotherapy techniques in patients with PD: A randomized control study

W. Kamel, M. Asala, A. Al-Tajalli, A. Al-Tammar, R. Alkhaldi, C. Ramos Jr, A. Mubarak (beni suef, Egypt)

Effects on voice sound level and brain connectivity after HiCommunication: a novel speech and communication treatment for Parkinson’s disease

H. Steurer, F. Albrecht, A. Razi, J. Körner Gustafsson, E. Franzén, E. Schalling (Stockholm, Sweden)

Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicentre, parallel, randomised, double blind, phase 2b clinical trial

C. Laurencin, A. Marques, D. Dilly Duchez, C. Giordana, S. Meoni, M. Anheim, P. Boulinguez, B. Ballanger, S. Thobois (Lyon, France)

Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease

J. Aldred, T. Henriksen, M. Bouchard, J. Martínez-Castrillo, M. Soileau, A. Spiegel, L. Bergmann, R. Gupta, P. Kukreja, D. Standaert (Spokane, USA)

Efficacy of a four-strain probiotic on gut dysbiosis, motor and non-motor symptoms in Parkinson`s disease: a multicentre randomised controlled trial

V. Leta, P. Zinzalias, J. Staunton, L. Batzu, D. Trivedi, F. Jernstedt, K. Rosqvist, J. Timpka, T. van Vliet, A. Podlewska, M. Parry, D. van Wamelen, A. Rizos, G. Chung-Faye, A. Borsini, C. Pariante, P. Odin, K. Ray Chaudhuri (London, United Kingdom)

Efficacy of levodopa/carbidopa/entacapone replacement of levodopa/dopa decarboxylase inhibitors in treatment of Chinese Parkinson’s disease patients with wearing-off: a multicenter, randomized controlled, open label study

CY. Yu, WG. Liu, AP. Gong, LH. Shen, H. Huang, Y. Zhao, CF. Liu (nanjing, China)

Enhancement of deep sleep in people with Parkinson disease using auditory stimulation of slow waves at home

SJ. Schreiner, S. Fattinger, J. Horlacher, G. da Poian, L. Kämpf, L. Brogli, W. Karlen, R. Huber, CR. Baumann, A. Maric (Zurich, Switzerland)

Experience of the LARGE-PD protocol in a health center in Buenos Aires, Argentina

N. Gonzalez Rojas, E. Gatto, I. Mata, C. Perandones, M. Inca, M. Cesarini, G. da Prat, J. Etcheverry (Buenos Aires, Argentina)

Exploring the complementary approach of a standardized osteopathic treatment protocol on sleep quality in Parkinsons disease: A randomized controlled study

S. Yao, J. Difrancisco-Donoghue, A. Leder, J. Mancini, J. Docherty (Old Westbury, USA)

Exploring the Effects of Spinal Cord Stimulation for Gait Disturbances in Parkinson’s Disease

N. Vanegas-Arroyave, K. Kwei, M. Lee, C. Prakash, L. Branco, A. Tarakad, Y. Taneff, N. Ince, A. Viswanathan, B. Najafi (Houston, USA)

Eye tracking paradigm to identify disease-specific behavioral biomarkers in neurodegeneration

M. Habibi, B. Coe, D. Brien, H. Riek, A. Janzen, W. Oertel, D. Munoz (Marburg, Germany)

Familial Parkinson’s: Epidemiological data at Blida University Hospital.

M. Benmahdjoub, K. Kesraoui, S. Bouchetara, M. Arezki (Blida, Algeria)

Foslevodopa/foscarbidopa in patients with advanced Parkinson’s disease: subgroup analyses from a phase 3, randomized study

M. Soileau, N. Fisseha, A. Jeong, T. Kimber, K. Klos, W. Robieson, S. Talapala, E. Vaou, H. Zheng, M. Facheris, R. Hauser (Georgetown, USA)

Foslevodopa/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson’s disease

L. Schlachter, S. Stodtmann, S. Talapala, M. Facheris, M. Rosebraugh (Ludwigshafen, Germany)

How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson’s disease patients: Experience from the Phase 3 clinical trial

R. Hauser, G. Banisadr, S. Fisher, H. Visser, R. D'Souza (Tampa, USA)

iCARE-PD: a multinational multicenter feasibility study of Integrated Care Networks in Parkinson disease

D. Dash, D. Grimes, J. Saade, R. Bouça, J. Ferreira, E. Ruzicka, A. Sanchez-Ferro, T. Lynch, M. van Munster, D. Pedrosa, M. Fabbri, O. Rascol, T. Mestre ()

Impact of endpoint selection on sample size calculations for disease-modifying clinical trials in Parkinson’s disease patients with GBA1 mutations

M. Fonseca, G. Castilla-Fernández, J. Liu, J. Holenz, N. Mendonça, D. Simon (Porto, Portugal)

Impact of istradefylline on the onset of dyskinesia in Parkinson’s Disease patients with wearing off: a randomized controlled study (ODYSSEI)

Y. Tsuboi, T. Hasegawa, Y. Shimo, S. Kaneko, M. Tomiyama, K. Kashihara, S. Chiu, T. Yamaguchi (Fukuoka, Japan)

Impact of the severity of Parkinson’s disease on skin elasticity

SY. You, HJ. Park (Daegu, Republic of Korea)

Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion

A. Antonini, B. Bergmans, D. Kern, P. Odin, L. Bergmann, R. Gupta, J. Homola, M. Shah, J. Zamudio, D. Standaert (Padova, Italy)

Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials

K. Chaudhuri, M. Bouchard, E. Freire-Alvarez, R. Pahwa, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (London, United Kingdom)

Improvements in Parkinson’s disease motor complications after treatment with opicapone: results from the OPTI-ON study

C. Kilbane, R. Drake, O. Klepitskaya, M. Serbin, E. Jen, S. Rattana, J. Trotter, G. Liang (Cleveland, USA)

In silico electrophysiology study reveals the modulating role of calcium channel on Subthalamic nucleus neuronal cells towards Parkinson’s disease

G. Kuanar, C. Mahapatra (Cuttack, India)

IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study: 4-year interim results

B. Bergmans, N. Winter, V. Schotte, N. Sys, L. Delameilleure, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges, Belgium)

Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Initiative

G. Mills, R. Chapman, S. Collins, R. Ellis-Doyle, C. Gonzalez-Robles, M. Zeissler, O. Bandmann, R. Barker, J. Carpenter, J. Chataway, J. Duffen, S. Gandhi, K. Mcfarthing, S. Mullin, A. Schapira, A. Schrag, C. Carroll, T. Foltynie (London, United Kingdom)

Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.

P. Odin, T. Kimber, B. Bergmans, E. Freire-Alvarez, F. Gandor, S. Isaacson, S. Dhanani, R. Hauser, M. O'Meara, A. Jeong, J. Jia, R. Gupta, L. Bergmann, M. Shah, L. Harmer, S. Talapala, J. Aldred (Lund, Sweden)

Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)

L. Guedes, D. Hilt, M. Fonseca, I. Peixoto, H. Gama (Coronado, Portugal)

Intercultural differences in patient and clinician perceptions of MDS-UPDRS in Parkinson’s disease

V. Kaasinen, S. Luo, P. Martinez-Martin, C. Goetz, G. Stebbins (Turku, Finland)

Investigating factors contributing to clinical trial recruitment in Parkinson’s Disease within the Black community

J. Adrissi, C. Onwumere, D. Dominguez, M. Lyleroehr, E. Gray, K. Williams, E. Zivin, D. Larson (Los Angeles, USA)

Is there impairment in neuromuscular trunk control in Parkinson disease when compared to healthy elderly?

H A. Araújo, A. Melanda, R. da Silva, S. Smaili (Londrina, Brazil)

Istradefylline effect on Parkinson’s Disease Tremor, Motor symptoms and non-Motor symptoms.

K. Chandrakumar, B. Wilmarth, B. Nagle, G. Di Maria, O. Gonul, L. Lovelace, E. Waldon, K. Getchell, Y. Torres-Yaghi, F. Pagan (Washington, USA)

Long term effects of Deep Brain Stimulation on Camptocormia in Parkinson’s disease

L. Nessis, C. Oehlwein, M. Oehlwein, W J. Schulz-Schaeffer (Homburg

Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial

C. Clarke, C. Rick, S. Patel, R. Wooley, N. Rowland, J. Futterer, R. Ottridge, C. Jenkinson, R. Gray (Birmingham, United Kingdom)

Long-term effects of a mobile technology-based brisk walking program on Parkinsonian symptoms in Parkinson’s disease – a randomized controlled trial

MKY. Mak, ISK. Wong-Yu (Hong Kong SAR, China)

Long-term evolution of advanced Parkinson’s disease burden: second interim results from the international PROSPECT observational study

P. Sanchez Alonso, O. de Fabregues, A. Lehn, T. Oeda, F. Ory-Magne, D. Safarpour, L. Bergmann, P. Kukreja, K. Onuk, V. Fung (Majadahonda, Spain)

Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.

J. Wallin, P. Svenningsson (Stockholm, Sweden)

Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson’s disease (PD): the LIXIPARK trial (NCT03439943)

WG. Meissner, P. Remy, C. Giordana, D. Maltete, P. Damier, JL. Houeto, C. Geny, L. Hopes, F. Durif, G. Defer, C. Tranchant, JC. Corvol, N. Carriere, JP. Azulay, S. Drapier, P. Krystkowiak, C. Thalamas, A. Benard, O. Rascol, N. Ns-Park/fcrin (Bordeaux, France)

NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.

H. Berven, S. Kverneng, E. Sheard, M. Søgnen, S. Geijerstam, K. Haugarvoll, GO. Skeie, C. Dölle, C. Tzoulis (Bergen, Norway)

Ocular microtremor in Parkinson’s Disease: Protocol for an observational pilot study

L. Graham, R. Morris, R. Vitorio, S. Stuart, A. Godfrey, R. Walker, C. Mcdonald (Newcastle, United Kingdom)

Online recruitment and retention in the Parkinson’s Progression Markers Initiative (PPMI)

C. Tanner, E. Brown, L. Chahine, D. Weintraub, R. Dobkin, W. Poewe, E. Tolosa, C. Marras, S. Schade, C. Coffey, M. Korell, C. Stanley, J. Valdeverde Twiggs, M. Kuhl, K. Fabrizio, S. Chowdhury, T. Sherer, A. Siderowf, T. Simuni, K. Marek (SAN FRANCISCO, USA)

Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease

V. Fung, J. Aldred, F. Bergquist, E. Danielsen, A. Jeong, J. Jia, A. Spiegel, S. Talapala, C. Carroll (Westmead, Australia)

Operationalising goal setting as an outcome measure: Experience from the PRIME-UK randomised controlled trial

E. Tenison, K. Lloyd, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

Parkinson’s Progression Markers Initiative (PPMI) prioritizes enrollment of individuals from diverse and underrepresented populations

R. Dobkin, M. Kutler, A. O'Grady, C. Kelliher, K. Greenwood, M. Kuhl, S. Fong, S. Mantri (Piscataway, USA)

Parkinson’s Progression Markers Initiative (PPMI): Defining PD biology to accelerate PD therapeutics

B. Mcmahon, A. Siderowf, T. Simuni, C. Tanner, B. Mollenhauer, C. Coffey, D. Galasko, K. Posten, L. Chahine, R. Dobkin, T. Froud, K. Kieburtz, D. Weintraub, K. Merchant, M. Frasier, T. Sherer, S. Chowdhury, E. Brown, R. Alcalay, A. Videnovic, K. Fabrizio, E. Flagg, K. Marek (New Haven, USA)

ParkProReakt Study Protocol – A randomized controlled trial to evaluate a proactive approach to health care in Parkinson’s disease

M. van Munster, J. Stümpel, N. Altschuck, L. Kerkemeyer, I. Wellach, D. Becker, M. Geraedts, D. Pedrosa (Marburg, Germany)

PASADENA 1-year open-label extension

G. Pagano, A. Reyes, A. Monnet, M. Martinec, N. Shariati, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Taylor, H. Svoboda, P. Fontoura, G. Kerchner, R. Doody, A. Bonni, T. Nikolcheva (Basel, Switzerland)

Path To Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson’s Disease: Study Design

C. Coffey, A. Siderowf, C. Tanner, K. Marek, M. Brumm, T. Simuni, P. Investigators, S. Chowdhury, T. Sherer, C. Kopil, K. Kieburtz, B. Saville, C. Allen-Savietta, B. Wendelberger, A. Crawford, K. Fabrizio ()

Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank compared to Abdomen in Parkinson’s Disease Patients

Y. Han, H. Kalluri, A. Jeong, C. Locke, M. Facheris, S. Gupta, M. Rosebraugh (North Chicago, USA)

Placebo response in Parkinson’s disease (PD) is predicted by expression levels of a specific brain network

J. Barbero, C. Tang, A. Vo, Y. Ma, S. Peng, B. Brakedal, C. Dölle, N. Brekke, C. Tzoulis, D. Eidelberg (Manhasset, USA)

Practice and outcome variation across Parkinson’s Foundation Centers of Excellence

C. Marras, N. Dahodwala, J. Beck, A. Naito, Z. Meyer, A. Ramirez-Zamora, M. Neault, M. Rose Rafferty, T. Davis, H. Liu (Toronto, Canada)

Preliminary Report on Neuromelanin-Sensitive MRI Signal change after Allogeneic Bone marrow-derived Mesenchymal Stem Cells therapy: Phase IIa double-blind, randomized controlled trial

J. Suescun, M. Schiess, E. Rodarte, C. Adams, T. Ellmore (Houston, USA)

Preliminary Report on the efficacy of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial.

M. Schiess, J. Suescun, C. Green, E. Tharp, S. Chandra, C. Adams, M. Shahnawaz, E. Rodarte, V. Thyne, T. Ellmore (Houston, USA)

Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial

J. Suescun, T. Ellmore, C. Adams, V. Thyne, E. Tharp, S. Chandra, C. Green, R. Shastri, J. Saltarrelli, M. Schiess (Houston, USA)

Proof-of-concept clinical trial: Prevent cognitive decline in GBA-associated Parkinson’s Disease

K. Brockmann, JC. Corvol, A. Difonzo, S. Durrleman, T. Gasser, M. Hu, R. Krüger, I. Liepelt-Scarfone, M. Matarazzo, A. Pilotto, T. Simuni, P. Svenningsson, D. Weintraub, G. Pagano (Tuebingen, Germany)

Psilocybin therapy for depression and anxiety associated with Parkinson’s disease: a pilot study (NCT04932434)

E. Bradley, K. Sakai, G. Fernandes, C. Ludwig, M. Bock, J. Ostrem, C. Tanner, A. O'Donovan, P. Finley, Z. Busby, A. Mckernan, R. Zuzuarregui, A. Penn, A. Wang, A. Theberge, R. Rosen, J. Woolley (San Francisco, USA)

Psychosocial factors impacting participation in a time-intensive deep brain stimulation study of individuals with Parkinson’s disease and dystonia

A. Hahn, S. Cernera, C. Racine, S. Little, P. Starr (San Francisco, USA)

Questionnaire for the detection of Parkinson’s disease

S. Abdraimova, R. Kaiyrzhanov, N. Zharkinbekova (Shymkent, Kazakhstan)

Randomized Controlled Trial comparing continuous intrajejunal levodopa infusion and deep brain stimulation for Parkinson’s disease. Cost-effectiveness and cost-utility outcomes of the INVEST study

D. van Poppelen, M. van Barreveld, R. de Bie, P. Schuurman, F. van Delft, G. Geurtsen, R. de Haan, M. Dijkgraaf, J. Dijk (Amsterdam, Netherlands)

Randomized, waitlist-controlled trial of Karate Intervention to Change Kinematic Outcomes in PD (KICK OUT PD)

J. Fleisher, K. Woo, B. Sennott, J. O'Keefe, C. Gill, S. Anderson, N. Purcell, B. Ouyang, J. Chodosh (Chicago, USA)

Rasagiline in Chinese patients with early-stage parkinson’s disease: a randomized, double-blind, placebo-controlled, delayed-start trial

W. Su, HJ. Liu, LJ. Wang, QY. Ye, L. Cao, HY. Zhou, XG. Luo, ZT. Ding, T. Wang, Q. Wang, HZ. Ma, EH. Xu, HB. Chen (Beijing, China)

Recruiting for Parkinson’s disease risk: Successful engagement tactics to screen for hyposmia in undiagnosed individuals

M. Kuhl, R. Dobkin, L. Lemon, C. Destro, C. Kelliher, T. Rosenbaum, N. Islam, K. Lynch, L. Heathers, M. Totten, E. Bryan, C. Stanley, C. Hobbick, B. Mcmahon, K. Fabrizio, K. Marek (New York, USA)

Recruiting people at risk of Parkinson’s disease: comparative data from PPMI Online and HeBA Kassel

E. Brown, S. Schade, S. Ghosh, K. Rege, V. Satagopam, M. Marti, W. Poewe, R. Kruger, C. Trenkwalder, L. Chahine, R. Dobkin, D. Weintraub, E. Tolosa, C. Marras, E. Bryan, J. Valverde Twiggs, M. Korell, K. Marek, B. Mollenhauer, C. Tanner (San Francisco, USA)

Recruitment of Parkinson’s disease patients with mild-to-moderate anxiety into a randomized controlled trial: Experience of a large Canadian tertiary movement disorders clinic

J. Lam, J. Zhu, D. Meng, P. Uzelman, S. Appel-Cresswell (Vancouver, Canada)

Reductions in OFF time with ND0612 for patients with Parkinson’s disease experiencing motor fluctuations: Responder-analysis from an open-label Phase 2 study

A. Ellenbogen, A. Espay, S. Isaacson, N. Lopes, N. Sasson, T. Yardeni, W. Poewe (Farmington Hills, USA)

Repurposing the MDS-UPDRS part III for early-stage Parkinson’s disease: Supportive evidence for a bradykinesia and rigidity specific sub-score

M. Key Prato, A. Regnault, S. Quéré, N. Massat, A. Benoit, T. Morel (Brussels, Belgium)

Results from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease

A. Antonini, S. Waters, C. Sonesson, J. Landström, N. Waters, J. Tedroff (Padova, Italy)

Safety and efficacy of P2B001 (low dose combination of extended-release pramipexole and rasagiline) in patients with early Parkinson’s disease: Subgroup analyses from a randomized, controlled trial

D. Falconer, P. Litman, H. Friedman, S. Oren, C. Fitter-Attas (Alexandria, USA)

Safety of foslevodopa/foscarbidopa during optimization and maintenance treatment: Post hoc analysis of a phase 3, single-arm trial

D. Kern, S. Isaacson, S. Dhanani, J. Aldred, B. Bergmans, D. Santos-Garcia, T. Oeda, F. Gandor, P. Kukreja, L. Bergmann, R. Gupta, S. Talapala, A. Spiegel, T. Kimber (Aurora, USA)

Stability and predictability of motor symptom control in patients with advanced Parkinson’s disease (aPD) receiving continuous subcutaneous foslevodopa/foscarbidopa (LDP/CDP)

R. Pahwa, I. Malaty, M. Soileau, V. Fung, D. Santos Garcia, C. Carroll, T. Henriksen, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, A. Spiegel, M. Facheris, M. Shah, P. Kukreja, J. Zamudio, K. Chaudhuri (Kansas City, USA)

STRAT-PARK: a biomarker and stratification initiative for Parkinson’s disease

K. Stige, S. Kverneng, S. Sharma, GO. Skeie, E. Sheard, M. Søgnen, S. Af Geijerstam, T. Vetås, C. Dölle, F. Dick, A. Wahlvåg, E. Berntsen, F. Riemer, P. Goa, K. Haugarvoll, S. Buch, D. Reese, D. Babiker, Y. Mahdi, T. Wade, G. Miranda, J. Ganguly, Y. Tamilselvam, J. Chai, S. Bansal, D. Aur, M. Haacke, M. Jog, C. Tzoulis (Trondheim, Norway)

Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease

T. Falk, S. Richards, M. Bartlett, A. Lind, C. Hsu, S. Sherman (Tucson, USA)

Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration

C. Gasca-Salas, P. Pineda-Pardo, M. Del álamo, T. Jiménez, C. Trompeta, L. García-Cañamaque, B. Fernández-Rodríguez, M. Matarazzo, I. Plaza Delasheras, E. Natera, R. Martínez-Fernández, S. Ruiz Deaguiar, J. Blesa, J. Obeso (Móstoles, Spain)

The effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial

M. Salari, N. Valian, L. Mohaghegh Shalmani, R. Rashedi, H. Ashourizadeh, L. Dargahi (Tehran, Islamic Republic of Iran)

The effect of lumboperitoneal shunt surgery on patients with iNPH plus Parkinson’s disease

T. Tsunemi, T. Shimada, A. Sakukrai, M. Nakajima, N. Hattori (Toyoo, Japan)

The feasibility and efficacy of speech therapy via video call in patients with Parkinson’s disease: a preliminary study

HJ. Chang, J. Kim, KA. Woo, JY. Joo, S. Kim, S. Lee, B. Jin, HY. Jeon, B. Jeon, HJ. Kim (Daejeon, Republic of Korea)

The impact of biographic factors and lifestyle on the symptoms of Parkinson’s Disease – a five year follow-up

J. Stögbauer, A. Bär, L. Schappe, U. Hillmann, K. Fassbender, C. Dupeyrat, D. Martens, J. Spiegel (Homburg, Germany)

The PD-Ballet study: a randomised controlled, single-blinded trial of dance therapy for Parkinson’s, baseline characteristics of the study cohort

A. Podlewska, L. Batzu, J. Staunton, P. Tall, V. Leta, M. Uribe Mz-Recaman, F. Derbyshire-Fox, A. Hartley, T. Soukup, R. Davis, N. Sevdalis, A. Healey, I. Bakolis, C. Pariante, A. Woods, K. Ray Chaudhuri (London, United Kingdom)

Timed-up-and-go tests under dual-task conditions: Influence of different tasks on gait parameters in Parkinsonian patients

C. Dupeyrat (HOMBURG, Germany)

Trial protocol: Randomized double blind controlled study to investigate disease modifying effect, safety and optimal dose of oral semaglutide tablet for patients with Parkinson’s disease (MOST-ABLE study)

Y. Kimura, T. Koda, H. Kurakami, S. Sakamoto, K. Iwasaki, H. Mochizuki (Suita, Osaka, Japan)

Trial site factor in Parkinson’s disease (PD) diary non-compliance

P. Reksoprodjo (Prague, Czech Republic)

Unsupervised physical capacity testing at home: a systematic review

D. de Graaf, S. Thissen, A. Van'T Hul, N. de Vries, B. Bloem (Nijmegen, Netherlands)

Update on the ADOPTION Study: Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies

J. Boyd, H. Fernandez, W. Poewe, A. Fasano, N. Kovács, K. Chaudhuri, M. Simu, J. Aldred, L. Lopiano, S. Parashos, J. Parra, L. Bergmann, P. Kukreja, M. Shah, O. Ladhani, G. Melzi, C. Yan, A. Antonini (Burlington, USA)